ea0029p1364 | Pituitary Clinical | ICEECE2012
Vroonen L.
, Lancellotti P.
, Tome M.
, Magne J.
, Auriemma R.
, Daly A.
, Pierard L.
, Beckers A.
Introduction: Since the 1990s cabergoline has become the treatment of choice in prolactinomas, allowing rapid and efficient hormonal and tumoral control in most cases. Evidence of cardiac valculopathy was demonstrated in patients treated by dopamine agonists for Parkinson disease, which led to curtailment of their use in this disease. Retrospective studies in hyperprolactinemia patients treated with cabergoline did not show such an effect, probably due to much lower dose...